(Q42874055)

9 November 2017

title

The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs (English)

1 reference

9 November 2017

1 reference

Apichart Atipairin

1

1 reference

9 November 2017

Bhutorn Canyuk

series ordinal

2

1 reference

9 November 2017

Adisorn Ratanaphan

series ordinal

3

1 reference

9 November 2017

language of work or name

English

0 references

publication date

29 September 2010

1 reference

Breast Cancer Research and Treatment

9 November 2017

published in

1 reference

9 November 2017

volume

126

1 reference

9 November 2017

issue

1

1 reference

9 November 2017

page(s)

203-209

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-010-1182-7

9 November 2017

exact match

0 references

cites work

BRCA1 and its toolbox for the maintenance of genome integrity

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Structure of a BRCA1-BARD1 heterodimeric RING-RING complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Identification of a RING protein that can interact in vivo with the BRCA1 gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Principles of ubiquitin and SUMO modifications in DNA repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

The UBXN1 protein associates with autoubiquitinated forms of the BRCA1 tumor suppressor and inhibits its enzymatic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

More modifiers move on DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Rapid recruitment of BRCA1 to DNA double-strand breaks is dependent on its association with Ku80

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Targeting DNA repair in breast cancer: a clinical and translational update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Fine tuning chemotherapy to match BRCA1 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

E3 ubiquitin ligases as cancer targets and biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Targeting the ubiquitin system in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Cisplatin Affects the Conformation of Apo Form, not Holo Form, of BRCA1 RING Finger Domain and Confers Thermal Stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Reactivity of platinum-based antitumor drugs towards a Met- and His-rich 20mer peptide corresponding to the N-terminal domain of human copper transporter 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Slowing of cisplatin aquation in the presence of DNA but not in the presence of phosphate: improved understanding of sequence selectivity and the roles of monoaquated and diaquated species in the binding of cisplatin to DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Alkaline hydrolysis of oxaliplatin--isolation and identification of the oxalato monodentate intermediate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

Towards Antitumor Active trans-Platinum Compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1182-7

10.1007/S10549-010-1182-7

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

9 November 2017

1044306091

0 references

1 reference